COMPANY

BrainStorm Cell Therapeutics

HQ: New York, NY source · brainstorm-cell.com ↗ · Mid-Atlantic

Keywords: neurology neurodegenerative diseases Amyotrophic Lateral Sclerosis Chronic Progressive Multiple Sclerosis NurOwn (MSC-NTF cells) Debamestrocel - MSC-NTF (NurOwn) Nurown MSC-NTF cells NurOwn® (MSC-NTF cells)

Location: New York, NY · source · Oct 14, 2026

Profile checked Oct 10, 2026

7Trials (company is sponsor)

Raises and deals from press releases

Raise Undisclosed round · $1M · announced Feb 20, 2026 Company release ↗
Source quote
- Feb 20, 2026 · Company release ↗
  “Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market”

Raises announced in these releases: $1M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Feb 20, 2026 Raise Undisclosed round · $1M source ↗
Jun 30, 2025 Trial start Phase 3: Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) source ↗
Mar 13, 2019 Trial start Phase 2: Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS source ↗
Aug 28, 2017 Trial start Phase 3: Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients source ↗
2014-05 Trial start 2: Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS source ↗
2012-12 Trial start Phase 2: Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) source ↗
2011-06 Trial start Phase 1/Phase 2: Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. source ↗

Upcoming milestones

Nov 1, 2028 (ESTIMATED) · Phase 3 · Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) · NCT06973629

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 7

Record	Title	Phase	Status	Start	Primary completion
NCT06973629	Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)	Phase 3	Not yet recruiting	Jun 30, 2025	Nov 1, 2028 (estimated)
NCT02017912	Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS	2	Completed	2014-05	2016-03 (actual)
NCT04681118	Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS	Not listed	No longer available	Not listed	Not listed
NCT03280056	Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients	Phase 3	Completed	Aug 28, 2017	Sep 29, 2020 (actual)
NCT03799718	Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS	Phase 2	Completed	Mar 13, 2019	Mar 11, 2021 (actual)
NCT01051882	Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.	Phase 1/Phase 2	Completed	2011-06	2012-12 (actual)
NCT01777646	Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)	Phase 2	Completed	2012-12	2014-09 (actual)